rs4220 — FGB Arg448Lys (R448K)

FGB Arg448Lys — Fibrinogen Beta Chain Variant Linking Clot Structure to Cardiovascular Risk

Fibrinogen is the principal protein of blood clotting. During coagulation, thrombin cleaves fibrinogen into fibrin monomers that polymerize into a mesh-like scaffold, which factor XIIIa cross-links into a mature clot. The fibrinogen beta chain (FGB)¹¹ fibrinogen beta chain (FGB)
one of three polypeptide chains — alpha, beta, and gamma — that assemble into the fibrinogen hexamer; the beta chain contributes to the central E-domain that controls fibrin polymerization kinetics and fiber thickness plays a critical role in determining the mechanical properties of the resulting clot. rs4220 changes a single amino acid in the mature beta chain — arginine to lysine at position 448 — and this seemingly minor substitution affects both how much fibrinogen circulates and how the resulting fibrin network is structured.

The Mechanism

The p.Arg478Lys substitution (position 448 in the mature processed protein, after removal of the 30-residue signal peptide) replaces arginine — a positively charged amino acid with a long guanidinium side chain — with lysine, which is also positively charged but shorter. The change alters the charge distribution and steric properties of the fibrinogen beta chain in a region that participates in fibrin-fibrin lateral aggregation during clot formation. Studies in African populations found that rs4220 is among the FGB variants whose interaction with total fibrinogen levels significantly influences fibrin clot properties — including fiber thickness, clot density, and susceptibility to fibrinolytic breakdown — independently of fibrinogen concentration alone.

The A allele also associates with modestly elevated plasma fibrinogen levels. Fibrinogen is an acute-phase reactant²² Fibrinogen is an acute-phase reactant
plasma levels rise two- to five-fold during inflammation or infection, making fibrinogen both a structural clotting protein and a sensitive marker of systemic inflammation. Elevated fibrinogen from genetic causes — as distinct from acute inflammation — may alter the fibrin network formed during clotting, producing denser clots with increased resistance to plasmin-mediated dissolution.

The Evidence

A prospective cohort study of 1,294 Chinese participants followed for hypertension development identified rs4220 as a predictor of incident hypertension specifically in men³³ A prospective cohort study of 1,294 Chinese participants followed for hypertension development identified rs4220 as a predictor of incident hypertension specifically in men
Ong et al. 2010 (Thrombosis and Haemostasis): among 178 men who developed hypertension from a normotensive baseline, the A allele conferred OR 1.52 (p=0.022); no significant association was found in women. The A allele was also independently associated with elevated baseline plasma fibrinogen levels (β=0.144, p<0.001), suggesting that the hypertension association is partly mediated through fibrinogen's effects on blood viscosity and endothelial shear stress.

A case-control study of 508 MI patients and 503 healthy controls in Chinese Han adults found the opposite direction of effect for coronary events⁴⁴ A case-control study of 508 MI patients and 503 healthy controls in Chinese Han adults found the opposite direction of effect for coronary events
Lu et al. 2008 (Chinese Medical Journal): K allele (A allele) carriers (KK+RK vs RR) had adjusted OR 0.71 for MI (p=0.023). This apparent paradox — elevated fibrinogen yet reduced MI risk — is consistent with evidence that the structural quality of fibrin clots, not merely circulating fibrinogen levels, determines cardiovascular risk. The Arg→Lys substitution may alter clot architecture in ways that reduce plaque-related arterial thrombosis while separately influencing blood pressure through viscosity effects.

A Mendelian randomization analysis of FGB variants including rs4220 in a large Danish cohort found that fibrinogen-increasing alleles produced a ~7% higher plasma fibrinogen level, but this genetically elevated fibrinogen was not associated with venous thromboembolism risk (PE or DVT)⁵⁵ A Mendelian randomization analysis of FGB variants including rs4220 in a large Danish cohort found that fibrinogen-increasing alleles produced a ~7% higher plasma fibrinogen level, but this genetically elevated fibrinogen was not associated with venous thromboembolism risk (PE or DVT)
Klovaite et al. 2013 (Am J Respir Crit Care Med). This Mendelian randomization finding argues against a causal role of fibrinogen levels in VTE, while leaving open a causal role in blood pressure regulation.

In a cross-sectional study of 480 community-dwelling adults, AA homozygotes at rs4220 showed approximately 12% lower carotid intima-media thickness (IMT) compared to other genotypes (Exp. β = 0.88, significant after adjustment for age, sex, BMI, exercise, and smoking)⁶⁶ In a cross-sectional study of 480 community-dwelling adults, AA homozygotes at rs4220 showed approximately 12% lower carotid intima-media thickness (IMT) compared to other genotypes (Exp. β = 0.88, significant after adjustment for age, sex, BMI, exercise, and smoking)
Wu et al. 2020 (PLoS One), consistent with the Chinese MI study's finding of a protective effect for the minor allele.

Evidence level is moderate: multiple studies across diverse populations with consistent fibrinogen-level effects, but contradictory associations for different cardiovascular endpoints, sex-specificity of the hypertension finding, and limited replication in prospective Western cohorts.

Practical Actions

The primary clinically actionable finding for rs4220 A carriers is the sex-specific association with hypertension development. Men carrying the A allele who have elevated fibrinogen levels should monitor blood pressure and fibrinogen periodically. The evidence does not support major changes in supplementation for heterozygotes; the AA homozygote state may warrant more active monitoring. The mixed evidence on cardiovascular outcomes underscores that fibrinogen level alone is an imperfect risk marker — the structural function of the fibrin network matters independently.

Interactions

rs4220 lies in the same gene as the well-studied promoter variants rs1800787 (FGB -148C>T) and rs1800790 (FGB -455G>A), which independently raise fibrinogen levels. Concurrent elevation of fibrinogen from both coding and regulatory FGB variants would be expected to compound the fibrinogen-level phenotype. The Kotzé et al. 2015 study identified interactions specifically between rs4220 and total fibrinogen levels in determining fibrin clot structure, suggesting that the coding variant modifies how elevated fibrinogen translates into clot architectural changes.

The rs6050 (FGA Thr312Ala) and rs6063 (FGG Gly191Arg) variants in the fibrinogen alpha and gamma chains respectively, when present alongside rs4220, may compound fibrin network dysfunction beyond what any single variant predicts.